The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

At Drexel University’s Graduate School of Biomedical Sciences and Professional Studies, graduate students and active ...

Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead ...

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

The FDA last week announced that it is looking into the safety of bluebird bio ’s gene therapy Skysona (elivaldogene ...

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

Projected to be worth over $38 billion in the global healthcare market by 2032, AI simulations have the potential to ...

Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...

Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington ...

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...